



Attorney's Docket No. 5470.148CX2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Baldwin et al.
Serial No.: 08/959,160
Filed: 28 October 1997
For: **Use of NF- κ B Inhibition in
Combination Therapy for Cancer**

Examiner: T. McKelvey

Group Art Unit: 1636

October 28, 2002

Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

NOV 07 2002

RECEIVED

#30/C
Zeta
11-7-02

RESPONSE AND AMENDMENT

Sir:

This is in response to the Official Action of May 28, 2002.

In the Claims:

✓ ✓ ✓
Please cancel claims 5, 11-12, and 17-28, without prejudice or disclaimer.

Please enter the following amended claims:

C 1. (thrice amended) A method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising administering to a mammalian subject in need of such therapy a therapeutically effective amount of an NF- κ B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of said NF- κ B inhibitor;

wherein said NF- κ B inhibitor is a proteasome inhibitor;

and wherein said antineoplastic chemotherapeutic agent is an anthracycline antibiotic.

C 2 3 (amended). The method of claim 1 where said chemotherapeutic agent is selected from the group consisting of daunorubicin, doxorubicin, mitoxantraone, and bisanthrene.